• 主题
高级搜索  >
历史搜索 清空历史
首页> 中文期刊> 《世界中医药杂志：英文版》 >Exploration of Bioactive Constituents and Immunoregulatory Mechanisms of a Hanshi-Yufei Formulation for Treating COVID-19

Exploration of Bioactive Constituents and Immunoregulatory Mechanisms of a Hanshi-Yufei Formulation for Treating COVID-19

         
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Objective:The objective of this study was to characterize the chemical compounds of a Hanshi-Yufei formulation （HSYF; a modified formulation of a traditional Chinese medicine used for treating COVID-19） to elucidate the mechanism of action and to evaluate potential anti-inflammatory effects of HSYF. Materials and Methods:The chemical constituents of HSYF extract were characterized using UPLC-Q-TOF/MS.Subsequently,asetofTCMnetworkpharmacologymethodswasappliedtoidentifydisease-associatedgenesandtopredicttarget profiles and pharmacological actions associated with the constituents of HSYF. Then, the antiviral effects of HSYF on H1N1 were assessed in RAW264.7 cells using MTT assays. Expression levels of pro-inflammatory cytokines interleukin （IL）-6 and tumor necrosis factor （TNF）-αfollowing infection of RAW264.7 cells with H1N1 were measured using an enzyme-linked immune sorbent assay （ELISA）, and expression levels of inflammatory-related factors were detected using western blotting. Results:In total, 165 chemical constituents （including glycosides,tannins, volatile oils, amino acids, triterpenoids, polyphenols, phenylpropanoids, sesquiterpenes, alkaloids, and flavonoids, among others） were tentatively identified in HSYF. Network pharmacology demonstrated that HSYF can regulate immunomodulatory-and anti-inflammatory-related targets of multiple pathways through its active ingredients, suggesting potential anti-COVID-19 effects. Furthermore, cell viability assays and ELISA showed that HSYF significantly inhibited H1N1 replication in RAW64.7 cells and markedly reduced expression of pro-inflammatory cytokines TNF-αand IL-6 at the proteins level. Conclusions:The results of the present study help improve our understanding of the therapeutic effects of HSYF in COVID-19 treatment from multi-level perspectives.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号